DPP4 and Parkinson disease: It was found that peroxisome proliferator-activated receptor-γ, GLP-1 and dipeptidyl peptidase-4 are important therapeutic targets for PD.3,4,5 Several in vivo and in vitro studies have reported neuroprotective effects of GLP1R agonists in experimental models of PD and AD [24].